Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ESPR
ESPR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ESPR News
ESPERION THERAPEUTICS STOCK RISES 2.5% FOLLOWING Q4 PROFIT TURNAROUND
12h ago
moomoo
Esperion Therapeutics Set to Announce Q4 Earnings on March 10
1d ago
seekingalpha
Esperion Outlines Future Growth Plans and Acquisition Strategy
9h ago
stocktwits
Esperion Reports Record Q4 2025 Earnings and Strategic Acquisition
10h ago
seekingalpha
Esperion Reports 21% Revenue Growth in FY25, Acquires Corstasis Therapeutics
15h ago
Newsfilter
Esperion Reports Q4 Earnings Beat with Strong Revenue Growth
15h ago
seekingalpha
Esperion Acquires Corstasis to Expand Product Line
Mar 03 2026
Benzinga
Esperion Acquires Corstasis for $75M to Enhance Cardiovascular Treatment
Mar 03 2026
seekingalpha
Esperion Acquires Corstasis, Launches First FDA-Approved Nasal Diuretic
Mar 03 2026
Newsfilter
Esperion Grants Restricted Stock Units to New Employees
Feb 11 2026
Newsfilter
Esperion Therapeutics Reports Strong 2025 Preliminary Results with $400 Million Revenue
Jan 12 2026
NASDAQ.COM
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy
Jan 12 2026
Globenewswire
Esperion's Bempedoic Acid Recognized by ACC as First-Line LDL-C Lowering Therapy
Dec 19 2025
Globenewswire
Esperion's Bempedoic Acid Recognized by ACC for LDL-C Lowering in PAD Patients
Dec 19 2025
Newsfilter
Esperion Grants 380,000 Stock Options and 435,536 RSUs to New CCO John Harlow
Dec 09 2025
Newsfilter
Piper Sandler Upgrades Esperion to Overweight Due to CV Franchise
Nov 25 2025
SeekingAlpha
Show More News
